Celgene, AstraZeneca launch four checkpoint studies; Gilead goes shopping;

@FierceBiotech: Merck KGaA puts a lead cancer drug on the chopping block; Threshold craters. Report | Follow @FierceBiotech

@JohnCFierce: I've got news of a sizable new biotech fund coming up at 6 EST. Stay tuned. | Follow @JohnCFierce

> Celgene ($CELG) and AstraZeneca ($AZN) have launched their collaboration around the PD-1 checkpoint inhibitor durvalumab. Investigators are starting four trials of the drug and therapeutic combinations against a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma. Release

> Gilead Sciences ($GILD), raking in revenue with its blockbuster hepatitis C therapies, is again talking up its plans for M&A, with R&D chief Norbert Bischofberger telling the Financial Times "we have incredible cash flows and we are looking for opportunities." Story

> Expanding her focus on the drug industry, Hillary Clinton has introduced a proposal to limit the effectiveness of tax inversions. More

Medical Device News

@FierceMedDev: ICYMI Friday: Google Life Sciences edges into Theranos terrain with needle-free, micro blood draw patent filing. Article | Follow @FierceMedDev

@VarunSaxena2: I've never seen a team invent so many ways to lose as the Detroit Lions! I knew it was coming! Unsure of call but it's the Lions after all. | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Cancer drug prices vary across the globe as countries strike deals with Big Pharma: Study. More | Follow @EmilyWFierce

> Danaher tags its industrial unit with the name 'Fortive' as part of the company split. More

> Cepheid nabs FDA OK for point-of-care flu test. Article

Pharma News

@FiercePharma: Scientists and ethicists debate 'gene editing' for animal health. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: ICYMI Friday: Sun to launch generic Gleevec Feb. 1 but has said it won't be manufacturing it at troubled Halol plant. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: If Pfizer's consumer health unit goes up for grabs, Reckitt's interested, CEO says. Report | Follow @CarlyHFierce

> Clinton keeps heat on drug industry with tax proposal for inversion deals. Report

> GSK delays Japanese drug launch after Catalent closes plant to investigate tampering. Article

Animal Health News

> Animalytix expands to Canada with acquisition of animal-health data service. Item

> Flu expert warns against USDA move to build bird flu vaccine stockpile. More

> Scientists and ethicists debate 'gene editing' for animal health. Story

> UMass seeks 5,000 dogs for study of genes and brain disorders. Report

> Supreme Court declines to review case on legality of online veterinary services. Article

Biotech IT News

> CDC taps uBiome for large-scale microbiome sequencing initiative. Report

> Genomics England picks Skyscape to provide cloud computing power to sequencing drive. Story

> AstraZeneca wants its scientists to interact on social media. More

> Kite teams with GE in bid to lower T cell production costs through automation. Item

> Venter's HLI adds genome interpretation software in Cypher Genomics buyout. Article

Pharma Marketing News

> Olympic snowboarder Kelly Clark 'vlogs' her acne-med experience for Sun Pharma. More

> AbbVie's Imbruvica, Amgen's Kyprolis shine at annual ASH meeting. Report

> GSK delays Japanese hair-loss treatment launch on Catalent plant problems. Item

> European group joins movement to stop industry cash flows to CME. Story

> With new rivals, Baxalta faces a hemophilia smackdown. So why is Shire bidding? Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.